China’s NMPA approves BeiGene’s Brukinsa to treat WM, CLL/ SLL
Pharmaceutical Technology
MAY 8, 2023
The small molecule Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa has been specially designed for delivering sustained BTK protein inhibition by optimising bioavailability, half-life, and selectivity. In April this year, the regulator converted these conditional approvals to regular approvals for R/R WM and R/R CLL/SLL.
Let's personalize your content